[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518248":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":210,"collaborators":31,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":31,"eligibilityCriteria":218,"healthyVolunteers":214,"sex":219,"minAge":220,"maxAge":31,"enrollmentInfo":221,"targetDuration":31,"studyType":224,"phases":225,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},{"fullName":5,"class":6},"Georgiamune Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous administration of GIM-122","EXPERIMENTAL","GIM-122",[13],"Drug: GIM122",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","GIM122","GIM-122 administered IV once every 3 weeks or every 2 weeks",[9],[11],[22],{"name":23,"affiliation":24,"role":25},"Omid Hamid, MD","The Angeles Clinic and Research Institute","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"LumaBridge CRO","CONTACT","210-563-8441",null,"contact@lumabridge.com",[34,52,64,77,93,109,126,143,159,178,193],{"facility":24,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Los Angeles","California","90025","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-118.24368,34.05223,{"lat":45,"lon":44},[48,50],{"name":31,"role":29,"phone":49,"phoneExt":31,"email":31},"310-294-0438",{"name":51,"role":25,"phone":31,"phoneExt":31,"email":31},"Omid Hamid, MD, PhD",{"facility":53,"status":35,"city":36,"state":37,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},"USC\u002FNorris Comprehensive Cancer Center","90033",{"type":42,"coordinates":56},[44,45],{"lat":45,"lon":44},[59,62],{"name":60,"role":29,"phone":31,"phoneExt":31,"email":61},"Thomas Won","thomas.won@med.usc.edu",{"name":63,"role":25,"phone":31,"phoneExt":31,"email":31},"Gino In, MD",{"facility":65,"status":35,"city":36,"state":37,"zip":66,"country":39,"countryCode":40,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"UCLA Hematology\u002FOncology","90095",{"type":42,"coordinates":68},[44,45],{"lat":45,"lon":44},[71,75],{"name":72,"role":29,"phone":73,"phoneExt":31,"email":74},"Thu Ly","310-794-3883","tply@mednet.ucla.edu",{"name":76,"role":25,"phone":31,"phoneExt":31,"email":31},"Bartosz Chmielowski, MD, PhD",{"facility":78,"status":35,"city":79,"state":37,"zip":80,"country":39,"countryCode":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"UCSF Helen Diller Family Comprehensive Cancer Center","San Francisco","94143",{"type":42,"coordinates":82},[83,84],-122.41942,37.77493,{"lat":84,"lon":83},[87,91],{"name":88,"role":29,"phone":89,"phoneExt":31,"email":90},"Markee Micu","415-319-3400","markee.micu@ucsf.edu",{"name":92,"role":25,"phone":31,"phoneExt":31,"email":31},"Katy Tsai, MD",{"facility":94,"status":35,"city":95,"state":96,"zip":97,"country":39,"countryCode":40,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Florida Cancer Specialists","Sarasota","Florida","34232",{"type":42,"coordinates":99},[100,101],-82.53065,27.33643,{"lat":101,"lon":100},[104,107],{"name":105,"role":29,"phone":106,"phoneExt":31,"email":31},"Kandyce Treijo","941-377-9993",{"name":108,"role":25,"phone":31,"phoneExt":31,"email":31},"Manish Rajni Patel, MD",{"facility":110,"status":35,"city":111,"state":112,"zip":113,"country":39,"countryCode":40,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Norton Cancer Institute","Louisville","Kentucky","40202",{"type":42,"coordinates":115},[116,117],-85.75941,38.25424,{"lat":117,"lon":116},[120,124],{"name":121,"role":29,"phone":122,"phoneExt":31,"email":123},"Juanita Dwingelo, MS, PhD, ACRP-CP","502-629-3681","juanita.vondwingelo@nortonhealthcare.org",{"name":125,"role":25,"phone":31,"phoneExt":31,"email":31},"Jaspreet Grewal, MD, PhD",{"facility":127,"status":35,"city":128,"state":129,"zip":130,"country":39,"countryCode":40,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Rutgers Cancer Institute of NJ","New Brunswick","New Jersey","08903",{"type":42,"coordinates":132},[133,134],-74.45182,40.48622,{"lat":134,"lon":133},[137,141],{"name":138,"role":29,"phone":139,"phoneExt":31,"email":140},"Taryn Bollaro","732-853-3229","tb509@cinj.rutgers.edu",{"name":142,"role":25,"phone":31,"phoneExt":31,"email":31},"Sanjay Goel, MD",{"facility":144,"status":35,"city":145,"state":146,"zip":147,"country":39,"countryCode":40,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Tennessee Oncology, PLLC","Nashville","Tennessee","37203",{"type":42,"coordinates":149},[150,151],-86.78444,36.16589,{"lat":151,"lon":150},[154,157],{"name":155,"role":29,"phone":31,"phoneExt":31,"email":156},"Amber Hilyard","ahilyard@tnonc.com",{"name":158,"role":25,"phone":31,"phoneExt":31,"email":31},"Jeffery S Russell, MD, PhD",{"facility":160,"status":35,"city":161,"state":162,"zip":163,"country":39,"countryCode":40,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Texas Oncology - Baylor Sammons Cancer Center","Dallas","Texas","75246",{"type":42,"coordinates":165},[166,167],-96.80667,32.78306,{"lat":167,"lon":166},[170,173,176],{"name":171,"role":29,"phone":172,"phoneExt":31,"email":31},"Charles Cowey, MD","214-370-1000",{"name":174,"role":29,"phone":175,"phoneExt":31,"email":31},"Stephanie Cannon","972-490-2939",{"name":177,"role":25,"phone":31,"phoneExt":31,"email":31},"Thomas Hutson, DO",{"facility":179,"status":35,"city":180,"state":162,"zip":181,"country":39,"countryCode":40,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"NEXT Oncology Dallas","Irving","75039",{"type":42,"coordinates":183},[184,185],-96.94889,32.81402,{"lat":185,"lon":184},[188,191],{"name":189,"role":29,"phone":190,"phoneExt":31,"email":31},"Alexis Praytor","972-893-8800",{"name":192,"role":25,"phone":31,"phoneExt":31,"email":31},"Shiraj Sen, MD, PhD",{"facility":194,"status":35,"city":195,"state":196,"zip":197,"country":39,"countryCode":40,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Virginia Commonwealth University","Richmond","Virginia","23298",{"type":42,"coordinates":199},[200,201],-77.46026,37.55376,{"lat":201,"lon":200},[204,208],{"name":205,"role":29,"phone":206,"phoneExt":31,"email":207},"Faith McFadden","804-628-0616","mcfaddenfr@vcu.edu",{"name":209,"role":25,"phone":31,"phoneExt":31,"email":31},"Jonathan Berkman, MD",{"type":211,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100518248","phase-1-safety-and-tolerability-study-of-gim-122-in-subjects-with-advanced-solid-malignancies-100518248",false,"NCT06028074","Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","A First-in-Human, Open-Label, Phase 1\u002F2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies","Inclusion Criteria:\n\nGeneral\n\n* Written informed consent\n* ECOG performance status 0-1.\n* Laboratory assessment 28 days prior to enrollment for assessment of acceptable cardiac, renal and hepatic functions\n* Recommended Double methods of contraception 90-days post treatment Cancer Specific\n* Histologically or cytologically confirmed locally advanced\u002Funresectable or metastatic solid tumor\n* Received FDA approved treatment of PD-1 inhibitor or PD-L1 inhibitor for advance malignant tumors and have progressed\u002Frelapsed, are refractory, or intolerant\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* Had prior therapy with PD-1\u002FPD-L1 inhibitors. Other checkpoint inhibitors (ie, CTLA4, LAG3) are permitted if they did not lead to treatment discontinuation\n* No other lines of therapy that are available\n\nExclusion Criteria:\n\nGeneral\n\n* Enrolled in any other interventional clinical trial, starting within 4 weeks of the first dose of GIM-122 and throughout the duration of the study, or is receiving other therapy directed at their malignancy\n* Women who are pregnant or breastfeeding\n* History of cardiac issues, pulmonary embolism, active and clinically significant bacterial, fungal, or viral infection ≤ 6 months prior to dosing\n* Contraindications to the imaging assessments or other study procedures that subjects will undergo or any medical or social condition that, in the opinion of the investigator, might place a subject at an increased risk, affect compliance, or confound safety or other clinical study data interpretation Cancer Specific\n* Current second malignancy at other sites\n* Leptomeningeal disease\n* Spinal cord compression\n* Symptomatic or new or enlarging central nervous system (CNS) metastases\n\nTreatment-specific Exclusion Criteria\n\n* Ongoing toxicity \\> Grade 1 from prior therapy according to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0\n* Has undergone a major surgery \\\u003C 1 month prior to administration of GIM-122\n* Has received radiation therapy within 2 weeks prior to administration of GIM-122\n* Has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem cell transplantation at any time\n* Has received systemic anti-cancer therapy within 2 weeks and cytotoxic agents that have a major delayed toxicity within 4 weeks, of the first dose of GIM-122\n* Prior treatment with other immune modulating agents within \\\u003C 4 weeks prior to the first dose of GIM-122.\n* Has a diagnosis of immunodeficiency, either primary or acquired\n* Has received treatment with systemic steroids or any form of immunosuppressive therapy within 14 days prior to administration of GIM-122\n* Has active or prior history of autoimmune disease, including ulcerative colitis and Crohn's disease, or any condition that requires systemic steroids.\n* Has a known severe intolerance to or hypersensitivity reactions to monoclonal antibodies, Fc-bearing proteins, or IV immunoglobulin preparations; prior history of human anti-human antibody response; known allergy to any of the study medications, or excipients in the various formulations of any agent.\n* Has received live vaccines within 30 days of study initiation (inactivated vaccines are allowed; seasonal vaccines should be up to date \\> 30 days prior to administration of GIM-122).","ALL","18 Years",{"count":222,"type":223},111,"ESTIMATED","INTERVENTIONAL",[226,227],"PHASE1","PHASE2","GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 \u002F 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.",[230],"Advanced Solid Malignancies",[232,233,11],"solid tumor","advanced malignancies","2025-07-08",{"date":236,"type":237},"2025-07-11","ACTUAL",{"date":239,"type":237},"2023-12-12",{"date":241,"type":223},"2026-12",{"name":5,"class":6},11]